

# Ali Manouchehrinia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9506768/publications.pdf>

Version: 2024-02-01

56  
papers

2,172  
citations

236612

25  
h-index

243296

44  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2631  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	4.9	210
2	Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. <i>Brain</i> , 2013, 136, 2298-2304.	3.7	127
3	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 139-143.	1.7	126
4	Effect of Smoking Cessation on Multiple Sclerosis Prognosis. <i>JAMA Neurology</i> , 2015, 72, 1117.	4.5	124
5	Importance of early treatment initiation in the clinical course of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1233-1240.	1.4	121
6	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1938-1946.	1.4	107
7	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 324-331.	0.9	95
8	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
9	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020, 94, e1201-e1212.	1.5	88
10	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1224-1233.	1.4	86
11	Long-term disability progression of pediatric-onset multiple sclerosis. <i>Neurology</i> , 2019, 92, e2764-e2773.	1.5	69
12	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1028.	4.5	68
13	Disability worsening among persons with multiple sclerosis and depression. <i>Neurology</i> , 2019, 93, e2216-e2223.	1.5	63
14	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.5	61
15	Predicting risk of secondary progression in multiple sclerosis: A nomogram. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1102-1112.	1.4	53
16	Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades. <i>JAMA Neurology</i> , 2019, 76, 665.	4.5	52
17	Clinical course of multiple sclerosis: A nationwide cohort study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1488-1495.	1.4	48
18	The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2017, 8, 675.	1.1	43

#	ARTICLE	IF	CITATIONS
19	Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1091-1095.	0.9	41
20	Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 329, 24-34.	1.1	41
21	Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. <i>Multiple Sclerosis Journal</i> , 2019, 25, 104-112.	1.4	37
22	A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1071-1079.	1.4	34
23	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 589-595.	1.4	32
24	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
25	Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis. <i>Frontiers in Neurology</i> , 2018, 9, 232.	1.1	31
26	Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 761-767.	0.9	23
27	Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. <i>Neurology</i> , 2020, 94, e932-e941.	1.5	20
28	Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 592-600.	2.0	19
29	Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 158-161.	0.9	19
30	Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. <i>Journal of NeuroVirology</i> , 2017, 23, 839-844.	1.0	17
31	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021, 12, 647811.	1.1	17
32	Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101414.	0.9	16
33	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	1.4	14
34	Income in Multiple Sclerosis Patients with Different Disease Phenotypes. <i>PLoS ONE</i> , 2017, 12, e0169460.	1.1	13
35	Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. <i>Journal of Neurology</i> , 2019, 266, 481-486.	1.8	13
36	Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 14987.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Alcohol Consumption and Risk of Common Autoimmune Inflammatory Diseases—Evidence From a Large-Scale Genetic Analysis Totaling 1 Million Individuals. <i>Frontiers in Genetics</i> , 2021, 12, 687745.	1.1	12
38	Smoking Attributable Risk in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 840158.	2.2	11
39	Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. <i>BMJ Open</i> , 2015, 5, e007806-e007806.	0.8	10
40	Characterization of annual disease progression of multiple sclerosis patients: A population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 786-794.	1.4	10
41	Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment. <i>PLoS ONE</i> , 2019, 14, e0217208.	1.1	10
42	Depression and multiple sclerosis: A bidirectional Mendelian randomisation study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1799-1802.	1.4	9
43	Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. <i>Annals of Neurology</i> , 2022, 91, 417-423.	2.8	8
44	Multiple sclerosis treatment effects on plasma cytokine receptor levels. <i>Clinical Immunology</i> , 2018, 187, 15-25.	1.4	7
45	Importance of early treatment decisions on future income of multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095911.	0.5	6
46	Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 131-135.	0.9	4
47	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686.	1.0	4
48	Similar familial risk in multiple sclerosis subgroups. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1782-1785.	1.4	3
49	A multiple sclerosis disease progression measure based on cumulative disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852098863.	1.4	3
50	A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2022, 132, 403-412.	0.8	2
51	Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210924.	0.5	2
52	P243—Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, .	0.9	2
53	Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. <i>Neurology</i> , 2020, 95, 1026-1026.	1.5	1
54	Season of birth is associated with multiple sclerosis and disease severity. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110657.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Re: Declines in the diagnosis of primary progressive MSâ€”A critical change in phenotype or critical measurement error?. Multiple Sclerosis Journal, 2017, 23, 305-307.	1.4	0
56	Association of Multiple sclerosis with Other Autoimmune Diseases. , 2013, , 341-356.		0